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Hair Follicle Stem Cell-Specific PPARc Deletion
Causes Scarring Alopecia
Pratima Karnik1, Zenar Tekeste1, Thomas S. McCormick1, Anita C. Gilliam1, Vera H. Price2,
Kevin D. Cooper1 and Paradi Mirmirani1
Primary cicatricial or scarring alopecias (CA) are a group of inflammatory hair disorders of unknown
pathogenesis characterized by the permanent destruction of the hair follicle. The current treatment options are
ineffective in controlling disease progression largely because the molecular basis for CA is not understood.
Microarray analysis of the lymphocytic CA, Lichen planopilaris (LPP), compared to normal scalp biopsies
identified decreased expression of genes required for lipid metabolism and peroxisome biogenesis.
Immunohistochemical analysis showed progressive loss of peroxisomes, proinflammatory lipid accumulation,
and infiltration of inflammatory cells followed by destruction of the pilosebaceous unit. The expression of
peroxisome proliferator-activated receptor (PPAR) g, a transcription factor that regulates these processes, is
significantly decreased in LPP. Specific agonists of PPARg are effective in inducing peroxisomal and lipid
metabolic gene expression in human keratinocytes. Finally, targeted deletion of PPARg in follicular stem cells in
mice causes a skin and hair phenotype that emulates scarring alopecia. These studies suggest that PPARg is
crucial for healthy pilosebaceous units and it is the loss of this function that triggers the pathogenesis of LPP.
We propose that PPARg-targeted therapy may represent a new strategy in the treatment of these disorders.
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INTRODUCTION
Cicatricial or scarring alopecia (CA) are a diverse group of
hair disorders that cause permanent destruction of the
pilosebaceous unit. CAs that result from follicular loss
because of thermal burns, metastatic cancer, trauma, and
radiation are referred to as secondary (Stenn et al., 1999;
Price, 2006). Primary CAs are characterized by a folliculo-
centric inflammation with the ultimate replacement of the
follicle with fibrous tissue and progressive and permanent
hair loss (Stenn et al., 1999; Price, 2006). The etiology and
pathogenesis of CA remains unclear and they are currently
treated as inflammatory disorders. Depending on the
inflammatory cells detected during the active phase of the
disease, CA are classified as lymphocytic (Lichen planopilaris
(LPP), frontal fibrosing alopecia, chronic cutaneous lupus
erythematosus, pseudopelade (Brocq), central centrifugal
alopecia, alopecia mucinosa, and keratosis follicularis
spinulosadecalvans), neutrophilic (folliculitis decalvans,
tufted folliculitis, and dissecting cellulitis), and mixed
(folliculitis keloidalis and erosive pustular dermatosis; Mir-
mirani et al., 2005). The clinical features of all these disorders
include destruction of hair follicles, progressive hair loss, and
permanent replacement of the follicle with fibrous tissue. The
destructive inflammatory changes in all primary cicatricial
alopecias occur in the infundibular region and, to a more
variable degree, the isthmic region of hair follicles (Figure 1a
and b). It is hypothesized that the permanent destruction of
hair follicles in scarring alopecia may be because of
destruction of hair follicle stem cells located in the follicular
bulge region (Cotsarelis and Millar, 2001).
The sebaceous glands (SG) are common victims along
with the hair follicle in CA (Stenn et al., 1999). SG are
appendages connected to the hair follicle to form the
pilosebaceous unit (Figure 1a). The function of SG in humans
is obscure, although it is known to secrete sebum composed
of a unique mixture of lipid metabolic products (Downie and
Kealey, 1998). The SGs are thought to facilitate the
coordinated breakdown of the inner root sheath (IRS) during
the hair cycle, and thus may be critical for follicular
regeneration (Stenn, 2001). Spontaneous mouse mutants,
Asebia (Josefowicz and Hardy, 1978) and defolliculated
(Porter et al., 2002), harbor hypoplastic sebaceous glands that
may be the pathological cause of scarring alopecia in these
models. Similar observations have been made with sebac-
eous adenitis with hyperkeratosis in dogs and cats (Stenn
et al., 1999). In humans, the extent of sebaceous gland
atrophy varies in different patients. Therefore, it is unclear as
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to whether CA results primarily from an abnormality or loss of
sebaceous glands or from a deregulated inflammatory attack
on follicular stem cells, although these two possibilities are
not mutually exclusive. Thus, a molecular mechanism linking
permanent loss of the hair follicle, sebaceous gland atrophy,
and inflammation is warranted to develop effective new
therapy for CA.
Peroxisome proliferator-activated receptors (PPARg, a,
and d) are members of the nuclear receptor super-gene
family that regulate the expression of genes involved in
inflammation and lipid homeostasis (Wahli, 2002). They
exhibit unique expression patterns within vertebrate tissues
and are central regulators of gene expression and differentia-
tion in several tissues including skin (Kuenzli and Saurat,
2003), sebaceous glands (Rosenfield et al., 1999), and the
immune system (Cabrero et al., 2002). Previous studies have
shown that PPARd is the most abundant PPAR in the adult
epidermis, although PPARg is more abundant than PPARd or
PPARa in sebocytes. PPARg plays a unique role in initiating
the differentiation of sebocytes in the sebaceous gland and
PPARd is believed to induce sebocyte maturation (Rosenfield
et al., 1999). These expression patterns may change during
hyperplasia, differentiation, and inflammation. Previous
studies in keratinocytes and epidermis have shown that
activation of PPARg stimulates keratinocyte differentiation,
improves permeability barrier homeostasis, and stimulates
epidermal lipid synthesis (Schmuth et al., 2008). The
activation of all three PPARs is anti-inflammatory and
interferes with many components of the inflammatory
response by altering the expression of cytokines, receptors,
and adhesion molecules (Cabrero et al., 2002). The broad-
spectrum regulatory potential of PPARg in lipid metabolism
and in controlling the inflammatory response suggests a
crucial role for this nuclear receptor in the maintenance of
the pilosebaceous unit.
Here, we report that PPARg-regulated pathways are
deficient in the lymphocytic CA, LPP. PPARg agonists can
induce the expression of these downregulated genes in
human keratinocytes. Finally, targeted deletion of the PPARg
gene in the stem cells of the follicular bulge in mice causes
scarring alopecia that resembles human disease. These
findings reveal a previously unreported role for PPARg in
maintenance of healthy pilosebaceous units and suggest that
the loss of this function likely triggers the pathogenesis of LPP.
RESULTS
Histopathology of LPP scalp biopsies
The lymphocytic CA, LPP, is the focus of our study here.
Patients with clinical diagnosis of LPP had early active lesions
that were judged clinically representative of primary cicatricial
alopecia (Otberg et al., 2008). Affected biopsy specimens were
taken from the ‘‘active border’’, an area with inflammation and
retained (but decreased) hair follicles. These were paired with
samples from clinically unaffected areas in the same patient. At
the active border of the affected patches, there is perifollicular
erythema and perifollicular scale. Anagen hairs may be easily
extracted from the active edge. In contrast, in unaffected scalp,
there is no loss of follicular markings, and there is no erythema
or scale. A pull test may only result in a few (B2–5) telogen
hairs. As previously reported (Mirmirani et al., 2005), we
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Figure 1. Histology of normal and LPP scalp tissue. (a) Structure of the human hair follicle and the sebaceous glands (the pilosebaceous unit). The hair follicle
stem cells are located in the hair follicle bulge region (b) between the arrector pili muscle (APM) and the sebaceous gland (SG). Other parts of the hair
follicle depicted are the outer root sheath (ORS), inner root sheath (IRS), bulb (Bb), dermal papilla (DP), and matrix (M). (b) In scarring alopecias, inflammation
occurs in the permanent portion of the hair follicle (infundibular region; striped area). Hematoxylin and eosin (H&E) staining of scalp biopsy sections (region
of sebaceous glands) of normal at (c;  10) and (d) Well-formed pilosebaceous units ( 20). LPP tissue sections (infundibular region) at (e;  10) and (f;  20)
have very few hair follicles, atrophied sebaceous glands, and dense lymphocytic infiltrate around many hair follicles. Scale bar¼ 25 mm.
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observed that the histopathology of unaffected tissue looked
near normal or showed very early histological changes (mild
infundibular lymphocytic inflammation and early sebaceous
gland atrophy).
In LPP, the scalp is often the only site of involvement with
patchy or diffuse hair loss. In the active stage of disease, the
histology of affected areas of scalp is very characteristic with
dense lymphocytic infiltrate around many follicular epithelia
(Figure 1e and f). The end stage is characterized by
perifollicular fibrosis, scarring, and replacement of preexist-
ing follicles with fibrotic tracts. Hematoxylin and eosin (H&E)
staining of affected LPP sections at the infundibular region
showed dense lymphocytic inflammation, atrophy of sebac-
eous glands, and loss of hair follicles, consistent with LPP
histopathology (Figure 1e and f). Normal controls were age
and sex matched with LPP patients. Normal controls
examined had no evidence of hair or skin disorders, their
scalp biopsies showed well-formed sebaceous glands, and
were devoid of inflammatory lesions (Figure 1c and d).
Comparative gene-expression profiling of unaffected and
affected LPP
Very little molecular information is available about disease
initiation and evolution in LPP. We used gene-expression
profiling to understand the molecular pathogenesis of LPP.
Two sets of microarray experiments were performed. In the
first set, we compared gene-expression profiles of affected LPP
(N¼ 20, pooled) with normal scalp biopsies (N¼ 20, pooled)
by hybridization to Affymetrix HG-U133 Plus 2.0 chips. Of
the B47,000 genes and expressed sequence tags represented
on these chips, 205 were upregulated and 219 were down-
regulated genes with 4twofold changes. To identify early or
primary events in the pathogenesis, we next compared gene-
expression profiles of paired unaffected (N¼10) and affected
scalp biopsies (N¼10) from LPP patients with normal controls
(N¼ 10). In this second experimental set where samples were
not pooled, 569 differentially expressed genes (182 upregu-
lated and 387 downregulated) were identified in unaffected
scalp biopsies (in at least 6 of 10 samples) compared to
normal controls (Tables 1 and 2).
In affected scalp tissue from the same patients, 446 genes
were differentially expressed in at least 6 of 10 samples (210
upregulated and 236 downregulated) compared to normal
controls. Although some patient to patient variation in gene
expression was seen, the core set of genes that were
differentially expressed in the pooled samples were also
differentially expressed in at least 6 of 10 individually
analyzed affected samples (Tables 1 and 2). The major
biological pathways in affected LPP tissue included inflam-
matory and cell death pathways as most significant among
upregulated genes and lipid metabolic and hair follicle
cycling and development pathways as most significant
among downregulated genes.
Increased expression of apoptotic, tissue remodeling, and
inflammatory genes in LPP
In concurrence with the histopathology of unaffected tissue
that looked near normal or showed very early histological
changes, the microarray data showed increased expression of
only three proinflammatory genes in all 10 unaffected tissue
samples from LPP patients. These were CD40 (TNFRSF5),
SPG21 and ARTS-1, genes required for activation of the
proinflammatory cytokine tumor necrosis factor-a (Table 1).
Data analysis with Ingenuity Pathways Analysis (Ingenuity
Systems, www.ingenuity.com), identified the NF-kB and
cytochrome P450 signaling as the most significant pathways
among upregulated genes (Figure S1a). The network model of
the NF-kB signaling pathway in unaffected tissue (Figure S1c)
shows that only proinflammatory factors such as NF-kB,
involved in T-cell activation (Baeuerle and Henkel, 1994),
are upregulated at this early stage of disease evolution.
In stark contrast to unaffected tissue, a large number of
inflammatory genes were upregulated in affected LPP tissue.
Figure S1f shows the complex inflammatory gene network in
affected LPP tissue compared to the inflammatory network in
unaffected tissue (Figure S1c). The majority of upregulated
genes in affected LPP were either required for tissue
remodeling and apoptosis or were inflammatory genes as
anticipated from histopathology. As shown in Table 1, we
observed a dramatic increase in gene expression of cytokines/
chemokines (MIP1, MCP1, CCL27, MMD, IL6, RANTES),
extracellular matrix-associated proteins (OPN, MMP1, MMP9,
MMP10, MMP28, TIMP4, ADAMTS1), apoptosis-related
genes (CASP1, GADD45B, PDCD6, PDCD4, CASP8)., and
cell-surface antigens (CD 68, CD 69), suggesting the activa-
tion of macrophages and T-lymphocytes, apoptosis, and
substantial matrix remodeling in LPP. Intriguingly, another
set of genes upregulated in LPP belong to the arachidonic
acid/COX/prostaglandin pathway (PTGER4, PTGS2, ALOX5-
AP) that is known to exert numerous immunoregulatory and
proinflammatory activities. The microarray-based gene ex-
pression changes in key inflammatory genes described in
Table 1 have been validated by real-time PCR analysis, using
RNAs used to generate microarray data as well as indepen-
dent sets of paired patient samples (Figure S2).
Thus, our observation that the majority of inflammatory
genes are upregulated in affected LPP but not unaffected tissue
suggests that although the components of the immune
signaling cascade, such as cytokines, chemokines, and
adhesion receptors, are important in disease progression, they
may not represent primary events in the pathogenesis of LPP.
Decreased expression of lipid metabolic and peroxisomal genes
in LPP
As shown in Figure S1b and e, the most significant biological
pathways downregulated in both unaffected and affected
tissue include lipid metabolism. Table 2 shows the compara-
tive expression of the majority of lipid metabolic genes in
unaffected and affected LPP tissue (changes observed in at
least 6 of 10 samples) compared to normal tissue. The largest
group of downregulated genes are those involved in fatty acid
metabolism (60 genes), fatty acid desaturation, elongation
and transport (10 genes), and cholesterol biosynthesis (10
genes; Table 2). In addition, genes required for hair follicle
development and function were also downregulated in
affected but not unaffected LPP tissue.
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The decreased expression of lipid metabolic genes in
unaffected LPP, including FADS2 (delta-6 desaturase), whose
expression is restricted to differentiating sebocytes in the
suprabasal layers of the sebaceous gland, cannot be
explained on the basis of sebaceous gland destruction alone.
As shown in Table 2, the gene expression of several lipid
metabolic genes (ACAA2, ACOT1, ACOX1, SOAT1,
HMGCR, HMGCS1, DHCR7, FADS1, FADS2, ELOVL4) is
decreased to a greater extent in unaffected compared to
affected tissue, although, the histological changes (sebaceous
gland atrophy) in unaffected tissue are near normal or mild
compared to affected tissue. This suggests that both histolo-
gical (mild sebaceous gland atrophy) and biochemical
(decrease in PPARg-mediated gene expression of lipid
metabolic genes) changes taking place in the pilosebaceous
glands contribute to lipid metabolic changes during disease
evolution. The microarray-based gene expression changes
were independently validated for representative genes by
real-time PCR analysis in normal, unaffected, and affected
LPP tissue (Figure S3). The effect of altered expression of lipid
metabolic genes could be deregulated lipid metabolism in
the pilosebaceous glands of LPP patients.
Table 1. Upregulated transcripts in unaffected and affected LPP tissue
GO biological process/
molecular pathway
Upregulated
transcripts in
unaffected LPP Upregulated transcripts in affected LPP
Number of
genes
affected
1 Immune function CD40 (TNFRSF5) (3.8),
SPG21(10.9), ARTS-1
(4.15)
NR4A1 (22), MIP3A (SCYA20) (20), OPN (ETA1) (17), CD69 (14.5), RANTES* (SCYA5)
(14), CD68 (6.9), IL6* (6), MIP2 (SCYB2)(5.7), MIP1a* (SCYA3) (5.3), MIP1b
(SCYA4)(5.3), MSR1 (SCARA1) (5), CD14 (3.3), MCP2 (3), MCP1* (SCYA2) (2.8),
MMD* (2.7), SCYA27 (CTACK)(2.7), HLA-C (9.2), HLA-A (5.3), B2M (5.3), HLA-G
(3.3) HLA-DQB1 (18.4), HLA-DRB1 (4.6), CD74 (3.73)
26
2 Tissue remodeling None MMP3 (128), MMP1 (52), MMP1 (45), MMP9* (22), MMP12 (13), CYR61 (11),
ADAMTS1 (5), PAI2 (3), TIMP4 (2.8), MMP28 (2)
10
3 Apoptosis None CASP1 (17.2), GADD45B (10), PDCD6 (8.6), DUSP2 (7), DUSP6 (7), PDCD4 (5.7),
CASP8 (2.5), CIDEA (2.64)
8
4 Eicosanoid
(prostaglandins/
leukotrienes) signaling
PTGER4 (55.72), PTGS2 (COX2) (6.52), PTGDS (4.3), Dicer 1 (3.8), ALOX5AP (2.9),
PTGFR (2.14)
6
5 Xenobiotic metabolism CYP1A1 (1020)) CYP1A1 (620), CYP2B7P1 (280) 2
GO, gene ontology; LPP, Lichen planopilaris.
*Indicates gene expression confirmed by real-time PCR. Fold changes for each gene are shown in brackets.
Table 2. Downregulated transcripts in unaffected and affected LPP tissue
GO biological
process/
molecular
pathway
Downregulated transcripts in unaffected tissue of LPP
patients
Downregulated transcripts in affected tissue of LPP
patients
Number
of genes
affected
1 Fatty acid
metabolism
PPARg (27), ACAA1 (8.7), ACAA2* (9.2), ACAD8 (8.7),
ACADM (5.9), ACSBG1 (7.6), ACSL1 (8.9), ACOT2 (17.5),
ACOX2* (5.5), ACOX1* (22), ALOX15B (6.1), SOAT1 (7.5),
AGPAT3 (10.4), ZAP128 (17.5), FABP7 (7), MLSTD1 (9)
PPARg (19), ACAA2*(2.8), ACAD8 (2.46), ACADM (4),
ACSBG1 (2.5), ACSL1 (2.8), ACOT2 (4), ZAP128 (5),
ACOX2*(6), ACOX1* (3), SLC27A2 (4), AMACR (2.5),
CRAT (2.8), ACAT2 (6.9), CYP4F8 (6.9), GK (4), ACSL5
(2.5), ALOX15B (6.9), HAO2 (2), HSD11B1 (3), PECR (6.9),
SOAT1 (2.8), AGPAT1 (2.6), etc.
60
2 Cholesterol
Biosynthesis
HMGCR (34.5), HMGCS1 (8.4), SOAT (7.5,), FDPS (5.6),
DHCR7* (5.8)
HMGCR (2.8), HMGCS1 (5), SOAT1 (2.8), MVD (3), PMVK
(2.4), DHCR7*(5), MVK (3), FDPS (6), NSDHL (2.6), EBP
(4),
10
3 Fatty acid
desaturation,
elongation, and
transport
FADS1* (8.9), FADS2* (21.5), FADS6 (14), ELOVL4 (27.8),
INSIG1 (4.5, )
FADS1*(6.9), FADS2*(6), ELOVL4 (4), INSIG1 (2.8),
ELOVL5 (8.5), ELOVL1 (2.8), FACVL1 (2), PCTP (2), LASS4
(3), SCARB2 (4)
10
4 Peroxisome
biogenesis
PEX3* (3.5), PEX16* (2.8)) PEX3*(10), PEX16*(6.9), PXMP2 (2.8), PEX 7 (5.8), PEX 11
(9)
5
8 Hair follicle genes None KRT 15 (7.5), KRT6B (4), KRT16 (6.9), KRT84 (8.5), KAP9-5
(2.8), KAP9-9 (2.6) etc.
48
GO, gene ontology; LPP, Lichen planopilaris.
*Indicates gene expression confirmed by real-time PCR. Fold changes for each gene are shown in brackets.
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We suspected that the effects of altered expression of lipid
metabolism genes would be reflected in the lipid composi-
tion of scalp tissue (sebum) in LPP. We therefore analyzed the
lipid profiles of paired unaffected and affected scalp biopsies
(N¼5) by gas chromatography. As shown in Table S1, lipid
analysis demonstrated a 43% decrease in cholesterol esters
and a 110% increase in triacylglycerols in affected scalp
compared to unaffected scalp biopsies from the same
patients. The fatty acid profile in all lipid fractions were also
altered with a significant increase in arachidonic acid and a
decrease in sapienic acid in affected LPP compared to
unaffected tissue (Table S1) in all lipid fractions tested (free
fatty acids, triacylglycerols, and phospholipids). Sapienic
acid is the major fatty acid in human sebum (Ge et al., 2003)
and is synthesized from linoleic acid by peroxisomal and
mitochondrial b-oxidation followed by desaturation (Delta 6-
and Delta 5-desaturase) pathways. These data validate
microarray and real-time PCR observations (Table 2 and
Figure S3) and suggest that deregulated lipid metabolism in
the pilosebaceous units of LPP patients, results in the
increased production of bioactive arachidonic acid that is a
precursor of proinflammatory lipids, the leukotrienes, and
prostaglandins.
Our data show that although lipid metabolic changes are
already seen in unaffected tissue, inflammatory changes take
place predominantly in affected tissue (Tables 1 and 2). This
suggests that lipid metabolic changes represent early or
primary events in disease pathogenesis. It also suggests that
deregulated lipid metabolism may be the cause rather than
the effect of the inflammatory response in LPP.
Deficiency of peroxisomes in LPP
Another group of genes that are downregulated in LPP are
those required for peroxisome biogenesis. Peroxisomes are
ubiquitous cell organelles that contain over 50 biochemical
pathways required for oxygen, glucose, hydrogen peroxide,
and lipid metabolism (Gould and Valle, 2000; Akimoto et al.,
2005). Genetic and proteomic studies in yeast and mamma-
lian cell systems have led to the identification of up to 32
proteins (collectively called peroxins or PEX) involved in
peroxisome biogenesis. In mammalian cells, three of these
peroxins (PEX3, PEX16, and PEX19) are specifically involved
in peroxisomal membrane protein (PMP) import (Wanders,
2004; Akimoto et al., 2005). Previous studies have shown
that when PEX3 or PEX16 proteins are absent or mutated in
cells, peroxisomes disappear (Schliebs and Kunau, 2004;
Heiland and Erdmann, 2005). Our microarray data (Table 2)
showed that PEX3, PEX16, and PMP22 are downregulated in
affected LPP. Again, as in the case of lipid metabolic genes,
we show (Table 2) that PEX3 gene is decreased significantly
in unaffected LPP tissue as well, suggesting that peroxisomal
changes are early events in LPP disease pathogenesis. As
many genes required for peroxisomal lipid metabolism are
also downregulated in LPP, we speculated that these cell
organelles may be defective in LPP. For visualization of
peroxisomes, scalp biopsy sections from normal controls
(N¼10) and paired unaffected and affected LPP (N¼10)
were stained with the peroxisomal membrane protein
PMP-70 and Alexa 488-labeled secondary antibodies. Nor-
mal scalp sections show PMP-70-positive ‘‘punctate’’ staining
pattern characteristic of peroxisomes (Shimozawa et al.,
2000; Heiland and Erdmann, 2005). Figure 2 shows abundant
staining of peroxisomes specifically in normal sebaceous
glands and in the inner (IRS) and outer (ORS) root sheaths of
the hair follicles. In contrast, scalp sections from LPP patients
lack PMP-70-positive peroxisome staining (Figure 2, LPP).
Double staining these tissue sections with the nuclear stain
DAPI, verified the presence of sebaceous glands, IRS, and
ORS in LPP (Figure 2, LPP, lower panel). Intriguingly,
unaffected tissue from LPP patients already begins to show
loss of peroxisomes in the IRS and ORS, although, sebaceous
glands still show peroxisome staining (Figure 2, uninvolved).
This suggests that peroxisomes may be lost before sebaceous
glands and demonstrates for the first time that LPP tissue
displays peroxisomal deficiency.
As shown in Figure 3, peroxisomal staining and confocal
microscopy of the ORS and IRS of hair follicle at higher
magnification (40) shows numerous PMP-70-positive par-
ticles in normal tissue (Figure 3a), but a complete absence of
peroxisomal staining in LPP tissue (Figure 3b). A minus
primary antibody control of normal tissue (Figure 3c) similarly
shows absence of peroxisomal staining. We observed auto-
fluorescence of tissue in the minus primary antibody control
(Figure 1c) that is masked by the bright staining of peroxi-
somes in normal tissue (Figure 1a). The PMP-70 immuno-
reactivity in normal (Figure 3d) tissue was significantly higher
compared to LPP (Figure 3e) and the minus primary antibody
control of normal tissue (Figure 3f) when the differences were
quantified by Surface Plot Analysis (ImageJ NIH software) that
provides a three-dimensional visualization of the intensity of
PMP-70-staining particles. Thus, the lack of identifiable
peroxisomal structures in LPP scalp tissue together with the
downregulation of PEX3, PMP22, and PEX16 suggests that
peroxisome deficiency may be because of an impairment of
peroxisome biogenesis in LPP.
PPARc regulates lipid metabolic and peroxisomal gene
expression
As a large number of inflammatory, lipid metabolic and
peroxisomal genes are differentially expressed in LPP, we
hypothesized that these genes may be regulated by a
common transcription factor or master regulator. In silico
promoter analysis (5 kb upstream of the transcriptional start
site) of differentially expressed genes with Multi-genome
Analysis of Positions and Patterns of Elements of Regulation, a
platform for computational identification of transcription
factor-binding sites (Marinescu et al., 2005) revealed PPAR
response elements on all downregulated genes (data not
shown). This provided preliminary evidence for the possible
involvement of PPARs in LPP disease pathogenesis.
Pathway and network analysis of differentially expressed
genes from unaffected and affected LPP tissue (Tables 1 and
2) were algorithmically generated based on information
contained in the Ingenuity Pathways Knowledge Base
(Ingenuity Systems, www.ingenuity.com). One such network
showed connectivity between PPARg and several key lipid
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metabolic genes including FADS1, ACOX1, ACAA1, and
ACSL1 suggesting that these genes are directly regulated by
PPARg (Figure S4). The PPARg network also shows a
functional interaction between PPARg and several of the
upregulated genes in affected LPP including CD36, SLC27A1,
and PTGS2 (COX2). Interestingly, these data suggest (Figure
S4a) a functional negative regulatory loop between PPARg
and PTGS2 (COX2). As shown in Table 1, PTGS2 (COX2)
gene expression is significantly increased (B6.5-fold) in
affected tissue of LPP patients. Functional analysis of the
PPARg network (Figure S4b) showed that the biological
functions and/or diseases that are most significant to the
genes in this network include lipid metabolism, arachidonic
acid and eicosanoid metabolism, and inflammatory diseases
in different systems. Thus, Ingenuity Pathways Analysis (IPA)
data suggests a possible role for PPARg in regulating lipid
metabolic and proinflammatory genes and the inflammatory
response in LPP.
To confirm the possible role of PPARg in LPP pathogenesis
derived through bioinformatics analysis, we determined the
gene-expression levels of the three PPAR isoforms in
unaffected and affected LPP and control tissue. Real-time
PCR showed that there was a significant decrease in PPARg in
unaffected and affected LPP (Figure 4a). In contrast, the
expression of PPARa and d remained unchanged in LPP
compared to normal controls (Figure 4a). Thus, isoform-
specific modulation of PPAR expression in LPP is suggestive
of a functional role for this master regulator in LPP disease
pathogenesis.
We directly assessed the role of PPARg in modulating
peroxisomal gene expression by growing human keratinocyte
cell line in the presence of PPAR agonists (1 and 5 mM
concentrations in 0.1% DMSO) and monitoring gene
expression by real-time PCR (Figure 4b). The agonists tested
were Ciglitazone (Cig), Rosiglitazone (Rosi), Pioglitazone
(Pio), and Troglitazone (Tro) that are specific for PPARg, WY-
14363 that is specific for PPARa, and GW50516 that is
specific for PPARd. Remarkably, WY-14363 and GW50516
had minimal effect on PEX16 gene expression at any
concentration tested. In contrast, Cig, Rosi, Pio, and Tro
induced a significant increase in PEX gene expression,
respectively, (Figure 4b). We also examined whether expres-
sion of the PEX3 gene is modulated by the PPAR agonist Pio
in cultured ORS cells. The ORS cells were grown in the
presence or absence of Pio and PEX3 gene expression was
monitored by real-time PCR. As observed with human
keratinocyte cell line (Figure 4b), PPARa (WY-14363) and
PPARd (GW50516) had minimal effect on PEX3 gene
expression in ORS cells (Figure 4c). In contrast, Pio induced
a significant increase in PEX3 gene expression at a
concentration of 1 mM (Figure 4c). To determine, if PPARg
negatively regulates COX2 gene expression, we treated hair
Normal Uninvolved
Uninvolved
LPP
LPPLPP
Figure 2. Peroxisome deficiency in LPP. Staining of peroxisomes with the anti-PMP-70 primary antibody for the peroxisomal membrane protein and Alexa 488-
labeled secondary antibodies. In normal scalp tissue (normal), a characteristic ‘‘punctate’’ pattern of peroxisome staining is seen specifically in the sebaceous
glands (SG) and in the ORS and IRS surrounding the hair shaft (HS). In unaffected tissue (uninvolved), peroxisome staining is lost in the ORS and IRS cells
surrounding the hair shaft but not in sebaceous glands. Double staining of the unaffected tissue sections for peroxisomes and nuclei with (DAPI) shows that the
ORS and IRS cells around the hair shaft are intact but the cells have lost peroxisomes (uninvolved, lower panel). Affected LPP tissue (LPP) shows a complete lack
of staining for peroxisomes in the sebaceous glands and in the ORS and IRS cells surrounding the hair shaft. In LPP tissue, peroxisome staining is not seen in both
the sebaceous gland and the hair follicle. Double staining the tissue for peroxisomes and nuclei reveals the presence of an intact sebaceous gland and hair
follicle in LPP tissue (right, lower panel), suggesting the specific loss of peroxisomes. Scale bar¼ 25mm.
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follicle outer root sheath cells (ORS cells) with PPAR agonists
and measured COX2 gene expression by real-time PCR. As
shown in Figure 4d, PPARg agonists significantly inhibit the
expression of the COX2 gene. In contrast, PPARa (WY-
14363) and PPARd (GW50516) agonists tested had minimal
effect on COX2 gene expression. These data suggest that in
human keratinocytes, it is the activation of PPARg and not
PPARa or PPARd that induces PEX16 and PEX3 gene
expression and represses COX2 gene expression. These
observations support our microarray and IPA data and suggest
that proinflammatory lipid metabolism and peroxisome
biogenesis in LPP are modulated by PPARg activity.
Together, these results suggest that PPARg is a master
regulator that controls complex functional networks linking
lipid metabolism and the immune response in the pilosebac-
eous units. It is likely that the loss of PPARg gene expression
in the pilosebaceous units, deregulates lipid metabolism and
elevates the expression of proinflammatory pathways such as
COX2 and 5-lipoxygenase (5-LO; Table 1), thereby inducing
an inflammatory response in LPP.
Possible role for xenobiotic metabolism as an environmental
trigger in LPP pathogenesis
Our microarray data showed that PPARg gene expression is
decreased significantly in unaffected and affected LPP tissue
(B27-fold in 6 of 10 unaffected LPP samples andB19-fold in
6 of 10 affected LPP). As shown in Figure S1a, the most
significant biological pathways upregulated in unaffected
tissue are cytochrome P450 signaling and xenobiotic
metabolism.
To confirm the role of xenobiotic metabolism in LPP, we
analyzed the microarray data from unaffected and affected
scalp biopsies with IPA-Tox(TM) within IPA application. The
IPA-Tox tool enables a mechanistic analysis of the xenobiotic
insult (not easily revealed by traditional methods) and helps
to rapidly understand biological responses in the tissue of
interest. As shown in the Figure S5, this analysis returned
several impacted toxicity lists in LPP, the most significant
being the Aryl Hydrocarbon Receptor (AhR) Signaling and
Xenobiotic Metabolism gene lists. The AhR signaling path-
way is a marker of xenobiotic metabolism. The CYP1A1 gene
that is a direct target of AhR is upregulated byB1,000-fold in
unaffected tissue (in 10 of 10 samples tested) and B500-fold
in affected LPP (in 10 of 10 samples tested). These data have
been validated by real-time PCR (data not shown).
Accumulating evidence in literature (Hanlon et al., 2003;
Cimafranca et al., 2004) has shown that the AhR suppresses
PPARg gene expression in response to dioxin-like com-
pounds. Thus, our data suggests a possible role for AhR as a
suppressor of PPARg gene expression and provides compelling
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Figure 3. Surface plot analysis of peroxisomes in normal scalp tissue sections and in LPP. High-magnification (40) confocal microscopy of (a) normal
scalp sections, stained for peroxisomes with the anti-PMP-70 primary antibody, yielded a punctate pattern indicating the presence of peroxisomal membranes
and intact peroxisomes. In LPP (b), no PMP-70-positive particles were visible indicating the complete absence of intact peroxisomes (c). Normal scalp
section minus primary antibody control showed an absence of peroxisomal staining. Three-dimensional graphs (d–f) of the intensities of pixels in the peroxisomal
images were determined by surface plot analysis with the NIH software Image J. The intensity of peroxisomal staining within a defined region (white rectangular
areas highlighted in a–c) is interpreted as height for the plot and gives a comparative semiquantitative measure of the number of peroxisomes within the region
in (d) normal, (e) LPP tissue and (f) normal minus primary antibody control. Scale bar¼ 25mm.
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evidence that xenobiotic metabolism may act as an environ-
mental trigger in the pathogenesis of LPP.
PPARc gene knockout targeted to stem cells of the follicular
bulge causes scarring alopecia in mice
To uncover the function of PPARg in the pilosebaceous unit
and its linkage to scarring alopecia-associated defects, we
used Cre-loxP-mediated gene targeting to delete PPARg in
stem cells of the hair follicle bulge using a stem cell-specific
promoter Keratin 15 (Liu et al., 2003). Floxed PPARg mice
(PPARg (f/f); He et al., 2003) contain loxP sites on either side
of the exons 1 and 2 of the PPARg gene. Cre-mediated
deletion of these exons is predicted to result in loss of PPARg1
and a nonfunctional, N-terminal, 43 amino-acid translational
product of PPARg2 that misses the partial AF1 domain and
the first zinc-finger of the DNA-binding domain (Zhu et al.,
1995). The floxed PPARg mice were crossed with a line of
mice that express Cre under control of the keratin 15
promoter (K15-Cre) to yield the follicular stem cell-specific
PPARg knockout (KO) mouse, PPARg (f/f)/Cre. Homozygous
PPARg-stem cell KO mice (PPARg (f/f)/Cre) were born at the
expected Mendelian frequency, suggesting normal early
development. Control mice were fl/fl littermates not expres-
sing Cre.
As shown in Figure 5a, floxed mice without Cre (PPARgfl/fl)
(male) had normal skin and hair phenotypes. In contrast,
PPARg (f/f)/Cre mice (PPARg stem cell KO mice; Figure 5a
and b) had normal skin and hair phenotype at birth;
however, starting at B3 months the mice displayed
progressive hair loss and increasing scratching behavior.
The PPARg-deficient mice also appeared to be slightly
smaller than wild-type littermates at B3 months. The
scratching behavior of these mice is reminiscent of pruritus
reported by LPP patients. Previous studies (Newton et al.,
1987; Mehregan et al., 1992; Tan et al., 2004; Mobini et al.,
2005) have shown that patients with active LPP almost
always report some degree of scalp itching and that pruritus is
the main symptom of human LPP. A close-up of the skin of
PPARg KO mouse (Figure 5c) displays flakiness, mild
erythema, and a region with complete loss of follicular
orifices. In advanced stage of disease, the skin of PPARg KO
mice appeared flaky and crusty and the remaining sparse hair
was matted and often difficult to remove at the time of
necropsy (data not shown).
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Figure 4. Altered PPARc gene expression in LPP and its effect on PEX and COX2 genes. (a) PPAR gene expression in normal and LPP tissue. Total RNA was
isolated from normal control (N¼ 10), unaffected LPP (N¼ 10), and affected LPP scalp tissue (N¼ 10) and PPARg, PPARa, and PPARd gene expression was
measured by real-time PCR. PPARg expression was significantly decreased in unaffected and affected LPP tissue. However, the expression of PPARa and PPARd
remained unchanged in LPP compared to control samples. (b) PPARg modulation affects PEX16 gene expression in vitro. HaCaT keratinocytes were treated with
vehicle alone (0.1% DMSO) or with specific agonists (1 and 5 mM in 0.1% DMSO) of PPARg–Ciglitazone (Cig), Rosiglitazone (Rosi), Pioglitazone (Pio), and
Troglitazone (Tro), PPARa-WY-14363 and PPARd–GW50516. After 48 hours, PEX16 gene expression was measured by real-time PCR. PPARg agonists
significantly induced the expression of PEX16 gene; however, PPARa and PPARd agonists had minimal effect. *represents P value p0.005. (c) PPARg
modulation affects PEX3 gene expression in outer root sheath (ORS) keratinocytes in vitro. In ORS cells, PPARg agonist (Pioglitazone) significantly induced PEX3
gene expression compared to vehicle alone (0.1% DMSO). In contrast, PPARa–(WY-14363) and PPARd (GW50516) agonists had minimal effect, suggesting that
PPARg regulates peroxisome biogenesis in the pilosebaceous units. (d) PPARg agonist (Pio) significantly inhibited COX2 gene expression in ORS whereas
PPARa–(WY-14363) and PPARd (GW50516) agonists had minimal effect, suggesting that PPARg negatively regulates COX2 expression.
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Hematoxylin and eosin-stained paraffin sections of the
skin from control littermates showed normal skin and hair
follicle histology (Figure 5d). In contrast, the PPARg KO mice
(Figure 5e), showed an obvious difference in the morphology
of hair follicles. H&E-stained sections of the skin of these
mice showed hyperkeratosis and follicular ostia that ap-
peared dilated and plugged. There was increased interstitial
inflammation. As shown in Figure 6, the PPARg KO mice
display several histopathological features of scarring alope-
cia. Dystrophic hair follicles, follicular plugging, and
perifollicular fibrosis were observed. In some cases, the
sebaceous glands appeared dystrophic and contiguous with
the follicular plugs. The dermis had progressively increasing
cellularity with interstitial inflammation. Perifollicular in-
flammation in the form of a mixed mononuclear infiltrate
consisting of lymphocytes, plasma cells, macrophages, and
mast cells was also observed (Figure 6).
In advanced disease, H&E staining of skin of PPARg KO
mice showed dystrophic hair follicles with sebaceous gland
atrophy (Figure 7a). Follicular scarring, in which fibrous
connective tissue strands run perpendicular to the epidermis
from remnants of dystrophic hair follicles, was also observed
(Figure 7b–d). The scarring seen in PPARg KO mouse skin
(Figure 7) is similar to scarring reported in the skin of Asebia
mouse (Sundberg et al., 2000, Skinbase–the mutant mouse
skin database http://eulep.pdn.cam.ac.uk/~skinbase/). In
contrast, the skin of normal mice (Figure 7a), showed
well-formed hair follicles.
Microarray analysis of the skin of PPARg KO mice
confirmed the histological data and showed a dramatic
increase in gene expression of chemokines (MIP1a, MIP1b,
CCR1, CD14), extracellular matrix-associated proteins
(MMP12, MMP8, TIMP2), and apoptosis-related genes
(CASP3, DUSP11; Table S2), suggesting the activation and
involvement of macrophages and T-lymphocytes. The data
also suggest that apoptosis and substantial matrix remodeling
may characterize the loss of hair follicles in PPARg KO mice.
In addition, as seen with human LPP tissue, microarray
analysis of the skin of PPARg KO mice showed decreased
expression of lipid metabolic and peroxisomal genes (Table
S3). These observations in the PPARg KO mice support our
studies with human tissue and suggest that decreased
Hyperkeratosis
Figure 5. Targeted disruption of PPARc in stem cells of the bulge resulted in scarring alopecia. (a) and (b) PPARgfl/fl/Cre mice (females, 3 months) with PPARgfl/fl
littermate (male). Hair loss occurs in a random patchy and progressive manner. The mice display severe scratching behavior and are smaller than their normal
littermates. (c) A close-up of the PPARgfl/fl/Cre mice shows a region with absence of follicular markings (indicated by arrow) and erythema suggesting the
presence of inflammation. The PPARgfl/fl littermates have normal skin and hair phenotype. Histology of skin of PPARgfl/fl and PPARgfl/fl/Cre mice by Hematoxylin
and eosin (H&E) staining of (d) PPARgfl/fl mice shows normal hair follicles and sebaceous glands. (e) H&E staining of a PPARgfl/fl/Cre mouse shows hyperkeratosis
and follicular plugging (indicated by arrow). The sebaceous glands appeared normal in the early stage disease (2–3 months). Scale bar¼ 50 mm.
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expression of lipid metabolic and peroxisomal genes is likely
a direct consequence of loss of PPARg expression.
Intriguingly, as seen with LPP tissue, microarray data of
PPARg KO mice showed a 64-fold increase in expression of
prostaglandin synthase (PTGS2 or COX2) and a 97-fold
increase in the expression of the lipid oxidation enzyme
5-LO-activating protein (ALOX5AP; Table S2). These data
support the Ingenuity Pathway data in LPP (Figure S4) and
suggests the existence of a negative feed-back loop between
PPARg COX2 and ALOX5A.
The animal data confirms our observations in LPP tissue
and suggest that the loss of PPARg expression activates the
proinflammatory lipid metabolic pathways that in turn induce
the inflammatory response and permanent hair loss in
Dystrophic hair follicles Follicular plugging
Dystrophic and
Interstitial inflammation Perifollicular inflammation
50 μM
normal sebaceous glands
Perifollicular
fibrosis
Figure 6. PPARcfl/fl/Cre mice show histopathological features of scarring alopecia. H&E staining of the skin of PPARgfl/fl/Cre mice showed (a) dystrophic hair
follicles, (b) follicular plugging, (c) dystrophic sebaceous glands, Scale bar¼ 20mm, (d) interstitial, and (e) perifollicular inflammation. Scale bar¼ 50 mm.
Figure 7. PPARcfl/fl/Cre mouse skin shows scarring. H&E staining showed (a) normal hair follicles in wild-type mouse skin (b) Dystrophic hair follicle with
sebaceous gland atrophy in the skin of PPARgfl/fl/Cre mice; (c–e) follicular scarring, in which fibrous connective tissue strands run perpendicular to the epidermis
from remnants of dystrophic hair follicles in PPARgfl/fl/Cre mouse 44 months of age (H&E;  40). Scale bar¼50 mm.
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scarring alopecia. The similarity in histopathology between
the PPARg KO mice and human LPP (perifollicular lympho-
cytic inflammation, fibrosis, scarring, and permanent hair
loss) suggests a crucial role for PPARg in the pathogenesis of
scarring alopecia.
DISCUSSION
Primary CAs are viewed as immune disorders caused by an
inflammatory attack in the permanent portion (infundibular
and/or isthmic region) of the hair follicle (Stenn et al., 1999;
Cotsarelis and Millar 2001; Mirmirani et al., 2005; Price,
2006). To understand the molecular pathogenesis of these
poorly understood hair disorders, we carried out global gene-
expression analysis of paired unaffected and affected scalp
biopsies from LPP patients compared to normal controls. The
majority of upregulated genes in affected LPP tissue were
either required for tissue remodeling and apoptosis or were
inflammatory genes as anticipated from histopathology. The
microarray data also revealed decreased expression of
multiple genes required for fatty acid b-oxidation, fatty acid
desaturation, cholesterol biosynthesis, and peroxisome bio-
genesis in LPP scalp tissue.
Intriguingly, the increase in expression of inflammatory
genes was seen in affected and not in unaffected tissue. In
contrast, the decreased expression of lipid metabolic genes
was seen to a greater extent in unaffected compared to
affected LPP tissue. These data suggest that the lipid
metabolic changes likely represent early or primary events
in disease pathogenesis. Our data also suggests that the lipid
metabolic changes may be the cause rather than the effect of
the inflammatory response in LPP. Lipid analysis by gas
chromatography showed a significant increase in arachidonic
acid in affected LPP compared to unaffected tissue, thereby
raising the possibility of arachidonate metabolites such as
leukotrienes and prostaglandins acting as proinflammatory
signals in LPP.
Indeed, biochemical pathway and promoter analysis of the
differentially regulated genes identified PPARg as an up-
stream regulator of the changes in LPP. These data also
revealed a negative regulatory loop between PPARg and
prostaglandin endoperoxide synthase 2 (COX2). The obser-
vation that PPARg agonists induce the expression of the
COX2 gene in ORS cells, provided experimental proof to
support the bioinformatics data. We identified a similar
negative feed-back loop between PPARg and 5-LO (data not
shown). Interestingly, both COX2 and ALOX5AP are sig-
nificantly upregulated in both LPP and in the PPARg KO
mouse, suggesting a role for these pathways in the
pathogenesis of scarring alopecia. The first rate-limiting step
in the conversion of arachidonic acid to prostaglandins is
catalyzed by PTGS2 (COX2), an enzyme that is associated
with biologic events such as injury, inflammation, and
proliferation. The 5-LO activating protein (ALOX5AP) is
necessary for activation of 5-LO that converts arachidonic
acid into leukotrienes, which are eicosanoid lipid mediators
of inflammation. Thus, elevated COX2 and 5-LO may lead to
the increased production and secretion of prostaglandins and
leukotrienes.
We have shown that there is a significant decrease in
expression of PPARg but not PPARa or PPARd in LPP. In vitro
studies in cultured human keratinocytes showed that specific
PPARg agonists induced the expression of peroxisomal genes
that are downregulated in LPP. Finally, hair follicle stem cell-
specific deletion of PPARg in mice causes scarring alopecia
with symptoms that parallel human disease. It is interesting to
note that in mice with a PPARg deficiency localized to the
epidermis, patchy hair loss was noted in older animals (Mao-
Qiang et al., 2004). Our data shows that targeted KO of
PPARg in the stem cells of the bulge causes scarring alopecia.
These results demonstrate that it is the dysfunction of stem
cells caused by loss of PPARg signaling rather than the
deletion of stem cells per se that likely triggers the
pathogenesis of CA. Together, these data provide compelling
evidence that PPARg deficiency leads to the accumulation of
proinflammatory lipids generated by 5-LO and COX2 path-
ways that trigger the pathogenesis of scarring alopecia.
A likely model for pathogenesis of primary CA is shown
(Figure 8). In normal pilosebaceous units, PPARg binds to
PPAR response elements and regulates peroxisome bio-
genesis and lipid metabolic genes thereby maintaining lipid
homeostasis. PPARg also has anti-inflammatory effects and
modulates the inflammatory response by regulating the
expression of proinflammatory lipid synthetic enzymes
(COX2, 5-LO), cytokines, chemokines, and adhesion mole-
cules. In primary CA, environment, diet, or genetic factors
likely suppress PPARg expression. The PPARg deficiency or
dysfunction in LPP patients induces peroxisome loss, disturbs
lipid homeostasis, and deregulates lipid metabolism in the
pilosebaceous unit. This causes the accumulation of proin-
flammatory lipids that in turn trigger chemokine/cytokine
expression, recruit lymphocytes and macrophages, and
causes tissue damage (lipotoxicity) and activates a lipid-
mediated programmed cell death (lipoapoptosis), thereby
contributing to permanent hair loss and scarring in LPP.
Altered sebaceous and epidermal lipids have been suggested
to be the cause of skin lesions seen in the Asebia mouse
(Wilkinson and Karasek MA, 1966; Brown and Hardy, 1988;
Sundberg et al., 2000). Thus, the accumulation of proin-
flammatory lipids in the pilosebaceous units of LPP tissue and
PPARg KO mice may induce an inflammatory response
because of lipotoxicity and contribute to CA pathogenesis.
Recent studies (Wan et al., 2007) have shown that PPARg
deficiency causes lipid accumulation in the lactating
mammary gland. These studies showed that PPARg defi-
ciency induces the production of inflammatory lipids in milk
that causes hair loss in nursing pups.
Accumulating evidence suggests that environmental pol-
lutants disrupt the body’s homeostatic controls through
deregulation of critical pathways involved in lipid metabo-
lism or energy balance. The genetic or environmental
mechanisms that initiate loss of PPARg signaling in LPP are
not fully understood. However, the skin as the outermost
barrier of the body is exposed to various sources of
environmental toxins such as dioxin or dioxin-like com-
pounds that are known to inhibit the expression of PPARg and
all lipogenic genes that are transcriptionally activated by
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PPARg (Liu and Jefcoate, 2006). Dioxin-like compounds exert
their biologic effects via the AhR, a ligand-dependent
transcription factor. The AhR is a ligand responsive transcrip-
tion factor that belongs to the basic helix-loop-helix Per-Arnt-
Sim (bHLH-PAS) superfamily. Upon binding ligands such as
dioxins, the AhR mediates an adaptive metabolic response by
upregulating the transcription of a battery of xenobiotic
metabolizing enzymes, including the cytochromes P450,
CYP1A1, CYP1A2, and CYP1B1 (Schmidt and Bradfield,
1996). Although epidemiologic links between dioxins and
scarring alopecia are lacking, it is interesting to note that our
microarray data showed the increased expression of dioxin-
inducible Cytochrome P1-450 (CYP1A1) gene in both
unaffected and affected LPP tissue, suggesting the constitutive
activation of AhR. In addition, toxicity analysis of unaffected
and affected LPP tissue with IPA-Tox(TM) identified the Aryl
Hydrocarbon Receptor Signaling and Xenobiotic Metabolism
as the most significant toxicity pathways involved in LPP.
Low levels of dioxin exposure have become a focus of
interest in the context of other PPARg involved diseases such
as adult-onset diabetes (Remillard and Bunce, 2002). Chronic
low-dose exposure may cause the accumulation of dioxins in
lipid-rich regions such as sebaceous glands and at a certain
threshold level (which may be reached at middle-age) may
cause the loss of PPARg expression and scarring alopecia in
susceptible individuals.
Whether the decrease in PPARg expression in LPP is
indeed the result of exposure to an environmental toxin or is
induced by dietary or genetic factors will require further
study. However, activation of PPARg signaling by PPAR
agonists could be effective in alleviating the deleterious
effects of inflammatory lipid accumulation in the pilosebac-
eous unit. Thiazolidinediones, that influence free fatty
acid flux, are known to activate PPARg (Berger et al.,
2005). Our data show that Rosi, Cig, Tro, and Pio induce the
expression of peroxisomal gene expression in LPP. Thus, it
seems likely that the stimulation of PPARg activity by specific
agonists could potentially inhibit the deleterious effects of
proinflammatory lipids such as inflammation, loss of hair
follicles, and scarring seen in LPP. Synthetic PPARg ligands
are currently used therapeutically in the treatment of
dyslipidemias, type 2 diabetes, cardiovascular disease, and
metabolic syndrome (Berger et al., 2005). Alternatively,
specific inhibitors of 5-LO pathway or specific COX2
inhibitors may provide previously unreported therapeutic
strategies for the treatment of scarring alopecias.
In summary, we show here that the loss of PPARg
expression in the stem cells of the bulge results in progressive
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Figure 8. Proposed model for the pathogenesis of primary cicatricial alopecia. In normal pilosebaceous units, PPARg binds to PPAR response elements (PPREs)
on target genes and maintains lipid homeostasis by regulating peroxisome biogenesis and lipid metabolism. PPARg also modulates the inflammatory response by
regulating the expression of cytokine genes. In primary CA, PPARg deficiency (either because of environmental or genetic factors) causes loss of peroxisome
biogenesis, deregulates lipid metabolism, and produces proinflammatory lipids that trigger an inflammatory response that in turn causes tissue damage and
permanent hair loss in CA.
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hair loss, sebaceous gland atrophy, scarring, and inflamma-
tion in a mouse model. These observations clearly implicate
primary defects of PPARg in the generation of scarring
alopecia. We believe the human disorder is a consequence of
PPARg deficiency that in turn induces a series of changes in
key metabolic pathways that induce the production of
proinflammatory lipids. We have shown that perturbation of
lipid metabolism induced by PPARg deficiency, most likely
an acquired condition, results in inflammation-induced
destruction of the pilosebaceous gland in CA. These effects
reveal a crucial role for PPARg in the maintenance and
normal functioning of the pilosebaceous unit and suggest that
loss of this signaling pathway may be responsible for the
pathogenesis of CA. To our knowledge, a link between
PPARg deficiency, deregulated lipid metabolism and hair
disorders in humans is previously unreported. Ongoing
studies in the PPARg KO mice should help to further refine
this hypothesis to genetically define disease progression in
primary cicatricial alopecia.
These observations provide a previously unreported
framework for understanding the role of PPARg in the
pathophysiology of primary cicatricial alopecia. Indeed,
PPARg agonists may represent a potential new therapeutic
strategy in the treatment of these disorders.
MATERIALS AND METHODS
Human tissue
Scalp biopsies were obtained from ‘‘the active border’’ (an area with
inflammation and retained but decreased hair follicles) from patients
with a clinical diagnosis of lymphocyte-mediated LPP and who were
seen at the clinics and University Hospitals of Cleveland or University
of California at San Francisco. All patients had active disease with
symptoms of itching, burning, or pain, and with progressive hair loss,
positive pull test, and evidence of inflammation. Patients were 18 years
or older and were able to give informed consent. These patients were
evaluated in a standard manner. This evaluation included a medical
history, detailed hair questionnaire, treatment history, examination of
hair, scalp, and skin, scalp photographs, and two 4mm scalp
biopsies—one from affected and another from clinically unaffected
scalp. Scalp biopsy specimens from healthy volunteers were included
as controls. All biopsies were done under the approval of the
University Hospitals Case Medical Center Institutional Review Board
and with the written, informed consent of patients and volunteers. The
study was conducted according to Declaration of Helsinki Principles.
All tissue samples were stored at 80 1C until processed. These
biopsies were utilized for total RNA extraction, microarray analysis,
real-time PCR, and immunofluorescence.
RNA isolation and microarray analysis
Total RNA from each biopsy was extracted using TRIzol (Life
Technologies Inc., Gaithersburg, MD) as per the manufacturer’s
instructions, followed by purification using RNeasy Mini
columns (Qiagen Inc., Valencia, CA). The RNA was quantitated by
spectrometry and used for microarray and real-time PCR
experiments.
Two sets of microarray experiments were performed. In the first
set, we analyzed samples of fresh frozen scalp tissue biopsied from
patients with LPP (n¼ 20, pooled) and compared the pattern of gene
expression against normal (control) scalp tissue (n¼ 20, pooled) by
interrogating the Affymetrix GeneChip oligonucleotide array Human
U133A 2.0 (Affymetrix, Santa Clara, CA). To confirm our observa-
tions with the first dataset and to identify early changes in LPP, a
second microarray experiment was performed with paired unaf-
fected (N¼ 10) and affected (N¼ 10) LPP scalp biopsies and
compared with normal scalp tissue (N¼ 10). Unlike the first
experiment, this set of samples were not pooled but were
individually analyzed with the Human U133A 2.0 array. This array
represents 18,400 transcripts and variants, including 14,500 well-
characterized human genes. Fluorescent Cy3- or Cy5-labeled cDNA
(Amersham Pharmacia Biotech, Piscataway, NJ) was synthesized
from 50 to 100mg total RNA, using oligo-dT-primed polymerization
with SuperScript II reverse transcriptase (Life Technologies). Hybri-
dization to the oligonucleotide arrays and subsequent washing and
detection was performed as described in the Affymetrix Expression
Analysis Technical Manual (Affymetrix). Array images were acquired
using a GeneChip Scanner 3000 (Affymetrix) and analyzed with
Genechip Operating Software (GCOS). The image from each
GeneChip was scaled such that the average intensity value for all
of the arrays is adjusted to a target intensity of 500 to take into
account the inherent differences between the chips and their
hybridization efficiencies. The Affymetrix program Netaffyx and
the Online Mendelian Inheritance In Man were used to identify the
functional significance, cellular location, and the role of genes in
various biological and metabolic processes.
Pathway analysis
Biologically relevant pathways were constructed using IPA applica-
tion (Ingenuity Systems, www.ingenuity.com). Detailed
methods and guide to interpreting IPA data are provided in the
Supplemental Methods section. The differentially expressed genes
containing Affymetrix identifiers and associated fold-change values
were uploaded for IPA analysis. The genes that had a fold change
greater than 2.0 were included in this analysis. Each gene identifier
was mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base. These genes, called focus genes, were
overlaid onto a global molecular network developed from informa-
tion contained in the Ingenuity Pathways Knowledge Base.
Networks of these focus genes were then algorithmically generated
based on their connectivity. The Functional Analysis of a network
identified the biological functions and/or diseases that were most
significant to the genes in the network. Fischer’s exact test was used
to calculate a P-value determining the probability that each
biological function and/or disease assigned to that dataset is
because of chance alone. The program also computes a score for
each network according to the fit of the network to the set of
focus genes.
Quantitative real-time RT-PCR
FAM-labeled PCR primers and TaqMan hydrolysis probes for all
target genes and 18S rRNA was purchased from Applied Biosystems
(Foster City, CA). Real-time PCR was performed on an ABI Prism
7700 Sequence Detection System (Applied Biosystems) according to
the recommendation of the manufacturer. The target gene expression
in LPP and control samples was quantitated by the comparative
computed tomography method as described in the ABI Prism 7700
Sequence Detection System manual (PE Biosystems).
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Immunohistochemistry
Scalp tissue specimens were cut horizontally or vertically and serial
sections were prepared using a cryostat (Leica Microsystems Inc.,
Bannockburn, IL). The slides were fixed in acetone and stored at
80 1C until immunostaining was performed. For the morphological
detection of peroxisomes, horizontal and vertical sections of scalp
biopsies were stained using the SelectFX Alexa Fluor 488 peroxi-
some labeling kit (Invitrogen-Molecular Probes, Carlsbad, CA),
following the recommendation of the manufacturer and visualized
by indirect immunofluorescence light microscopy. The kit utilizes
rabbit antibodies directed against the peroxisomal membrane
protein 70 (PMP-70), which is a high abundance integral-membrane
component of peroxisomes. In some instances, the slides were
counterstained with the nuclear stain DAPI. Antigen-antibody
complexes were detected under a Carl Zeiss Axioskop FL micro-
scope, using Alexa Fluor 488 goat anti-rabbit IgG antibody. The
approximate absorption and fluorescence emission peaks of the
Alexa Fluor 488 dye conjugate are 495 and 519 nm and the labeling
was observed using standard fluorescein filter sets. The slides were
cover-slipped with Vectashield mounting medium (Vector Labs Inc.,
Burlingame, CA).
Lipid analysis
Tissue lipids were extracted by the Folch method (Folch et al., 1957).
The chloroform phase containing lipids was collected, dried
under nitrogen, and subjected to methylation. Fatty acid methyl
esters were prepared by standard methods using BF3/methanol
reagent (14% Boron Trifluoride). Fatty acid methyl esters were
analyzed by gas chromatography using a fully automated HP5890
system equipped with a flame-ionization detector (Morrison and
Smith, 1964). The chromatography utilized an Omegawax 250
capillary column. Peaks were identified by comparison with fatty
acid standards (Nu-chek-Prep, Elysian, MN), and the area and its
percentage for each resolved peak were analyzed using a
PerkinElmer M1 integrator.
Effect of PPARc agonists and antagonists on PEX and COX2
genes
Human hair follicle ORS cells were obtained from ScienCell (San
Diego, CA) and grown in mesenchymal stem cell medium consisting
of 500ml of basal medium, 25ml of fetal bovine serum, 5ml of
mesenchymal stem cell growth supplement, and 5ml of penicillin/
streptomycin solution. Human keratinocyte cell line were cultured
in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum under 5% CO2 at 37 1C. The different PPAR agonists were
added in triplicate in dimethylsulfoxide (o0.1% by volume) for
48 hours to evaluate their effects on PEX and COX2 gene expression
by real-time PCR.
Generation of PPARc stem cell KO mice
PPARg stem cell KO mice (PPARg (f/f)/Cre) mice were generated by
intercrossing mice carrying floxed alleles of PPARg (He et al., 2003)
were crossed with a Cre-transgenic line K15-CrePR1 (Liu et al.,
2003), expressing Cre recombinase under the control of mouse
keratin complex 1, acidic, gene 15 promoter. Both mouse strains
were purchased from The Jackson Laboratory, Bar Harbor, Maine.
Littermates lacking the K15-Cre transgene were used as controls. All
experimental procedures were conducted in accordance with the
Guide for Care and Use of Laboratory Animals of the National
Institutes of Health, and were approved by the Case Western Reserve
University IACUC.
PCR genotyping was carried out by using the following primers.
For the Cre transgene, primers oIMR1084 (50-GCGGTCTGGCAG
TAAAAACTATC-30) and oIMR1085 (50-GTGAAACAGCATTGCTGT
CACTT-30) yield a 100 bp fragment. For identifying the floxed allele,
the following primers were used: oIMR1934 (50-TGTAATGG
AAGGGCAAAAGG-30) and oIMR1935 (50-TGGCTTCCAGTGCA
TAAGTT-30) amplify a 214 bp product from the wild type and a
250 bp product from the mutant (floxed) allele. Genomic DNA was
amplified by 35 cycles of 94 1C for 20 s, 60 1C for 30 s, and 72 1C for
55 s. Total RNA was isolated from mouse tissues by using TRIzol
(Invitrogen-Molecular Probes). Reverse transcription was performed
with SuperScript (Invitrogen-Molecular Probes, Carlsbad, CA). Sense
(50-GTCACGTTCTGACAGGACTGTGTGAC-30) and antisense (50-
TATCACTGGAGATCTCCGCCAACAGC-30) primers were designed
to anneal to regions in exons A1 and 4 of PPARg1, respectively,
which distinguish the full-length (700-bp) and recombined (300-bp)
transcripts. PCR was performed by 40 cycles of 94 1C for 20 s, 60 1C
for 30 s, and 72 1C for 60 s.
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